The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Telix Pharmaceuticals's Revenue for the
six
months ended in Dec. 2025 was $413.4 Mil. Telix Pharmaceuticals's average Accounts Receivable for the
six
months ended in Dec. 2025 was $126.4 Mil.
Hence, Telix Pharmaceuticals's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.27.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Telix Pharmaceuticals Receivables Turnover Related Terms
Telix Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLX vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (TLX) has a Receivables Turnover of 3.27 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Telix Pharmaceuticals and its competitors. According to the industry distribution chart, Telix Pharmaceuticals ranks #288 out of 839 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Telix Pharmaceuticals' Receivables Turnover too high?
Telix Pharmaceuticals' current Receivables Turnover is 3.27. The Biotechnology industry median Receivables Turnover is 5.27. Telix Pharmaceuticals' value of 3.27 is 38% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #288 out of 839 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #288 out of 839 companies for Receivables Turnover. This puts Telix Pharmaceuticals in the upper half of its industry. The industry median Receivables Turnover is 5.27. Telix Pharmaceuticals' value of 3.27 is 38% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Receivables Turnover of 3.27 is 38% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Receivables Turnover is 3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $31.24, compared to a current price of $11.74 — trading 62.4% below its estimated fair value. The current Receivables Turnover is 3.27 and 38% below the Biotechnology industry median of 5.27. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Receivables Turnover is 3.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.74 is trading 62.4% below its estimated GF Value™ of $31.24.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
Receivables Turnover: 3.27
GF Value™: $31.24 vs. price of $11.74 (62.4% below fair value)
Industry Position: 38% below the Biotechnology median (#288 of 839)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
